DeBoer M D, Gurka M J, Morrison J A, Woo J G
Department of Pediatrics, University of Virginia, Charlottesville, VA, USA.
Department of Health Outcomes and Policy, University of Florida, Gainesville, FL, USA.
Int J Obes (Lond). 2016 Sep;40(9):1353-9. doi: 10.1038/ijo.2016.81. Epub 2016 May 2.
The severity of the metabolic syndrome (MetS) is related to future incidence of type 2 diabetes (T2DM) and cardiovascular disease (CVD). However, the relationship between MetS severity and levels of fasting insulin and adiponectin-markers of insulin resistance-is unclear.
We used linear and logistic regression to analyze data from 711 participants of the Princeton Lipid Research Cohort with information regarding levels of insulin, adiponectin and MetS severity during 1998-2003 (mean age 39.5 years); 595 participants had MetS severity data from childhood (1973-1976, mean age 12.9 years) and 417 had updated disease status from 2010 to 2014 (mean age 50.9 years).
Childhood MetS Z-scores were positively associated with adult insulin levels (P<0.001) and negatively associated with adiponectin levels (P=0.01). In individual analyses, higher insulin levels and MetS Z-score as adults were related to higher odds of incident diabetes and CVD over the next 11.2 years (all P<0.001), whereas lower adiponectin levels were only related to odds of future T2DM (P<0.0001). In a model including insulin, adiponectin and MetS Z-score, adiponectin was not linked to future disease; both insulin (P=0.027) and MetS Z-score (P=0.002) were related to risk of future T2DM, while only MetS Z-score was related to future CVD (P<0.001).
The severity of MetS exhibits long-term links to levels of insulin and adiponectin, suggesting potential genetic and environmental influences on insulin resistance over time. As a long-term predictor of T2DM and CVD, the severity of MetS exhibited consistent independent correlations. This supports clinical utility in evaluating MetS severity as a predictor of risk for future disease.
代谢综合征(MetS)的严重程度与2型糖尿病(T2DM)和心血管疾病(CVD)的未来发病率相关。然而,MetS严重程度与空腹胰岛素水平和脂联素(胰岛素抵抗标志物)之间的关系尚不清楚。
我们使用线性和逻辑回归分析了普林斯顿脂质研究队列中711名参与者在1998 - 2003年期间(平均年龄39.5岁)有关胰岛素、脂联素水平和MetS严重程度的信息;595名参与者有儿童期(1973 - 1976年,平均年龄12.9岁)的MetS严重程度数据,417名参与者有2010年至2014年(平均年龄50.9岁)的疾病状态更新信息。
儿童期MetS Z评分与成人胰岛素水平呈正相关(P<0.001),与脂联素水平呈负相关(P = 0.01)。在个体分析中,成人较高的胰岛素水平和MetS Z评分与未来11.2年内发生糖尿病和CVD的较高几率相关(所有P<0.001),而较低的脂联素水平仅与未来T2DM的几率相关(P<0.0001)。在一个包含胰岛素、脂联素和MetS Z评分的模型中,脂联素与未来疾病无关;胰岛素(P = 0.027)和MetS Z评分(P = 0.002)均与未来T2DM的风险相关,而只有MetS Z评分与未来CVD相关(P<0.001)。
MetS的严重程度与胰岛素和脂联素水平存在长期关联,提示随着时间推移,可能存在对胰岛素抵抗的遗传和环境影响。作为T2DM和CVD的长期预测指标,MetS的严重程度呈现出一致的独立相关性。这支持了将评估MetS严重程度作为未来疾病风险预测指标的临床实用性。